![](https://webarchive.library.unt.edu/eot2008/20081025021359im_/http://www.cancer.gov/images/spacer.gif) |
|
![](https://webarchive.library.unt.edu/eot2008/20081025021359im_/http://www.cancer.gov/images/spacer.gif)
COX-2 inhibitor TG01 An orally bioavailable anti-inflammatory agent with potential antiangiogenic and antineoplastic activities. COX-2 inhibitor TG01 binds to and inhibits the enzyme cyclooxygenase-2 (COX-2), thereby inhibiting the conversion of arachidonic acid into prostaglandins. TG01-mediated inhibition of COX-2 may induce tumor cell apoptosis and inhibit tumor cell proliferation and tumor angiogenesis. COX-related metabolic pathways may represent crucial regulators of cellular proliferation and angiogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
![](https://webarchive.library.unt.edu/eot2008/20081025021359im_/http://www.cancer.gov/images/spacer.gif)
Code names: | ![](https://webarchive.library.unt.edu/eot2008/20081025021359im_/http://www.cancer.gov/images/spacer.gif) | TG01 TP2001 | | ![](https://webarchive.library.unt.edu/eot2008/20081025021359im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081025021359im_/http://www.cancer.gov/images/spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081025021359im_/http://www.cancer.gov/images/gray_spacer.gif)
![](https://webarchive.library.unt.edu/eot2008/20081025021359im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081025021359im_/http://www.cancer.gov/images/spacer.gif) |